ACN Newswire
Read More

FTLife launches “Protect Starter” Critical Illness Protector

indie
8 minutes

HONG KONG, Aug 22, 2022 - (ACN Newswire via SEAPRWire.com) - FTLife Insurance Company Limited ("FTLife") is committed to helping its customers embrace the "Championing Spirit" in life. Today, it is announcing the launch of "Protect Starter" Critical Illness Protector ("Protect Starter"), which is aimed at young people and first-time insurance buyers. At an affordable price, "Protect Starter" covers 76 common critical illnesses including cancer, stroke and severe heart attack etc. and all the congenital conditions of the covered critical illnesses that have not been detected at or before the policy issue. It also protects the insured until 100 years of age. Jarita Kwan, Chief Product Officer at FTLife, said, "Young people may think that they are not susceptible to critical illnesses, and therefore delay getting critical illnesses protection. However, they should capture this window of opportunity to enjoy lower premium as a young insurance buyer, that will enable them to receive timely help in the unfortunate incident of being critically ill and burdened with mounting medical bills. On the other hand, young people and first-time insurance buyers can feel daunted by the great number ...

SeaPRwire
Read More

Ways to protect your health coverage from life’s uncertainties

elean
6 minutes

Life can be unpredictable, and unexpected circumstances can crop up at any time, without warning. What does it take to be future-ready? Are you adequately prepared for life’s uncertainties? Having a financial plan may not be enough – you also need the right resources to manage the unpredictable events, which could include critical illnesses, accidents, calamities and even retrenchments. Any of these events could result in financial instability or distress. Insurance can offer you financial protection and help moderate those risks. According to a recent Manulife survey1, nearly 40 per cent of respondents who have battled critical illness have used up all or most of their savings, while half suffered serious financial problems after being diagnosed with critical illness. One in four borrowed money or remortgaged to finance treatments, while 20 per cent admitted to facing trouble paying for basic necessities. Another 6 per cent ended up declaring bankruptcy as a result of their critical illness. So, when it comes to managing unplanned situations in life, are you suitably prepared? Manulife’s health and protection insurance plans – LifeReady Plus (II), Critical SelectCare and Ready Com...

ACN Newswire
Read More

New treatment option for schizophrenia Reagila(R) listed on PBS

indie
5 minutes

MELBOURNE, Sep 6, 2021 - (ACN Newswire via SEAPRWire.com) - A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for the treatment of schizophrenia in adults.Schizophrenia is a complex psychiatric disorder comprising a range of symptoms - positive symptoms include hallucinations and delusions, while negative symptoms include social withdrawal and apathy. Affecting some 90,000 Australians, schizophrenia is our most stigmatised and disabling mental illness, with life expectancy nearly 15 years below the general population.Reagila, in-licensed by Seqirus, a wholly-owned subsidiary of CSL, is an atypical antipsychotic which indirectly targets two neurotransmitters in the brain: dopamine and serotonin. Neurotransmitters are considered the brain's 'chemical pathways'.Professor Ian Hickie, Co-Director for Health & Policy, The Brain and Mind Centre, University of Sydney and NHMRC Senior Principal Research Fellow said this listing highlights ongoing effort...

SeaPRwire
Read More

New treatment option for schizophrenia – Reagila(R) – listed on PBS this week

pandora
7 minutes

– Adults living with schizophrenia will have access to a new treatment option with Reagila(R) (cariprazine) now reimbursed on the Pharmaceutical Benefits Scheme from 1 September, 2021.1– There continues to be a significant, unmet need in treating schizophrenia. With a complex range of symptoms,2 treatment is not a “one size fits all”.3 This listing will give adults living with schizophrenia, another affordable, mental illness treatment.– Affecting approximately 90,000 Australians,4 schizophrenia is considered our nation’s most disabling, and heavily stigmatised mental illness,5 with the average life expectancy of those with the illness, 12.5 to 16.5 years below that of the general population MELBOURNE, Sept 3, 2021 – (ACN Newswire) – A new treatment for schizophrenia in adults, Reagila(R)(cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, 2021, providing patients with an additional treatment option.1 Schizophrenia is a complex psychiatric disorder2 comprising a range of symptoms, including positive symptoms, such as hallucinations and delusions,6,7 and negative symptoms, such as social withdrawal and apathy.8,9 Reagila(R) – in-licensed by Seqirus, ...